Ron Weitzman

Dr. Weitzman brings over 20 years of Oncology clinical development experience in the biotech and pharmaceutical industries where he has worked in all areas of clinical development including phase 1, 2 and 3 clinical trials. Dr Weitzman’s drug development experience includes both solid and hematological malignancies. He has interacted extensively with FDA, EMEA, Canadian and Japanese health authorities. Dr. Weitzman currently serves as the president of Weitzman Consulting Group LLC, a company that provides consulting services in all areas of Oncology drug development to pharmaceutical and biotechnology clients.

Prior to establishing his consulting company, Dr. Weitzman served as Vice President of Clinical Development at Exelixis, where he oversaw the global development of CABOMETYX®, spanning the period from its initial phase 1 study to subsequent approvals. Prior to Exelixis, he was Group Director at Genentech overseeing AVASTIN® development in NSCLC and GBM. He has also previously worked at Eli Lilly, and at Novartis where he played a key role in the development of TASIGNA®.

Dr. Weitzman holds an M.D. degree from The University of Western Ontario and completed an internal medicine residency at The Mount Sinai Hospital in NYC and a medical oncology fellowship at Columbia Presbyterian Medical Center.